Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 16/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3505519 | 0.86 | SIGMAR1 (0.42) | OPRD1KCNH2CYP2D6OPRK1OPRM1 | |
| SCHEMBL2452252 | 0.85 | OPRD1 (0.39) | OPRD1KCNH2CYP2D6 | |
| SCHEMBL2446498 | 0.83 | SIGMAR1 (0.49) | OPRD1KCNH2CYP2D6OPRK1OPRM1 | |
| SCHEMBL2451921 | 0.81 | ADRA1D (0.44) | KCNH2OPRM1SIGMAR1ADRA1DADRA1A | |
| SCHEMBL3509723 | 0.79 | OPRD1 (0.39) | OPRD1KCNH2CYP2D6OPRK1OPRM1 | |
| SCHEMBL3224637 | 0.76 | HTR2A (0.35) | — | |
| SCHEMBL3506534 | 0.75 | KMT2A (0.47) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL3222393 | 0.74 | HTR2A (0.34) | SIGMAR1 | |
| SCHEMBL2452349 | 0.74 | SIGMAR1 (0.52) | KCNH2CYP2D6OPRM1SIGMAR1 | |
| SCHEMBL12410068 | 0.73 | NISCH (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364982-A1 | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof | ONO Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| US-7498323-B2 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1619193-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | CCR1, CCR7, CCR3 | OPRD1 127/4885KCNH2 640/4885CYP2D6 778/4885 |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | CCR1, CCR7, CCR3 | OPRD1 127/4885KCNH2 640/4885CYP2D6 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.